Kim Moran – SVP & Head of US Rare Disease, UCB
Kim Moran, SVP & Head of US Rare Disease at UCB, discusses how the company is building on its long-standing heritage in neurology to expand into rare and ultra-rare conditions.…
UCB is a global biopharmaceutical company headquartered in Brussels, Belgium that focuses on neurology and immunology.
The company has more than 7,5000 employees, a strong market presence in about 40 countries, € 4.5 billion in revenue (2017) and numerous strategic partnerships across the industry.
Their core products are Cimzia®, Vimpat®, Neupro®, Keppra® and Briviact®, and they are preparing the launch of a potential medicine to help patients with osteoporosis.
Kim Moran, SVP & Head of US Rare Disease at UCB, discusses how the company is building on its long-standing heritage in neurology to expand into rare and ultra-rare conditions.…
Vivian Kuo, General Manager at UCB, brings over two decades of pharmaceutical industry expertise across medical affairs, marketing, corporate strategy and commercial excellence. Having spent seven years at UCB, progressing…
The latest stories from healthcare and the life sciences in Belgium, the Netherlands and Luxembourg (BeNeLux). UCB is considering a USD five billion investment in the US to avoid President…
Switzerland is the 22nd biggest country in Europe in terms of population yet plays host to a full 20 percent of the continent’s life science companies, with over 1,000 operational…
Intricacy, precision, and quality. These are bywords for Switzerland’s world-renowned watchmaking industry, but which could equally apply to its biopharmaceutical manufacturing footprint. As with top-end models from Rolex, Tag Heuer,…
Fabrice Véricel and Geoffrey Folie explore UCB’s strategic growth, highlighting its European sites in Braine-l’Alleud, Belgium and Bulle, Switzerland and their roles in global pharmaceutical production. Key topics include the…
A run-through of some of the most striking recent stories from pharma in the dynamic Asia-Pacific region, including Japan’s attempts to bring back Big Pharma investment; UCB’s decision to divest…
UCB has been undergoing a far-reaching digital business transformation, integrating novel approaches across its R&D organisation, including Computer-Aided Drug Design (CADD) and AI, while striving to maintain a patient-centric focus.…
Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in…
UCB Italy’s Managing Director, Federico Chinni offeres his insights into UCB’s positioning and its new product launches, the first for the company in ten years. He also weighs in on…
UCB’s general manager for Iberia, Pau Ricós, comments on the Belgian company’s upcoming launches, its focus on immunology and neurology, and the importance of R&D – UCB spent around 28…
Belgian champion UCB’s global manufacturing head, Jacques Marbehant, talks candidly about managing a broad global manufacturing and supply chain through the COVID-19 pandemic, the talent challenges inherent in scaling up…
See our Cookie Privacy Policy Here
